About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a publicly listed company based in Tarrytown (United States) founded in 1988 by Leonard Schleifer. It operates as an antibodies are developed for treating cancer, eye, and inflammatory diseases. The company has 15,110 employees. Regeneron Pharmaceuticals has completed 4 acquisitions, including Checkmate Pharmaceuticals, Decibel Therapeutics and LIBTAYO. Its chief executive is Leonard Schleifer. Its website regeneron.com draws about 324 thousand monthly visits. Its focus areas include Diversified Pharmaceuticals, Life Sciences, Immunotherapy and Antibody. Its competitors include Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, United States. Antibodies are developed by the company for applications in oncology, ophthalmology, and immunology. Key products include ARCALYST for inflammation, EYLEA for eye conditions, and PRALUENT as a PCSK9 inhibitor. Phase 3 and 2 pipelines address rheumatoid arthritis, asthma, atopic dermatitis, and other disorders. Annual revenues reached 12.17 billion in 2022, with net profit at 4.33 billion.
- Annual Revenue$14.34 B (USD)0.99as on Dec 31, 2025
- Net Profit$4.5 B (USD)2.09as on Dec 31, 2025
- EBITDA$4.25 B (USD)-8.83as on Dec 31, 2025
- Latest Funding Round$14.86M (USD), Grant
Aug 2010
- Investors
- Employee Count15,110
- Investments & AcquisitionsCheckmate Pharmaceuticals
& 3 more
Apps and channels of Regeneron Pharmaceuticals
its YouTube channel Regeneron has 2.41K subscribers and 30 videos.
Videos from Regeneron Pharmaceuticals
The most watched videos on Regeneron Pharmaceuticals's YouTube channel, Regeneron (2.41K subscribers). Click a video to play it here.
More on Regeneron.
Funding Insights of Regeneron Pharmaceuticals
- Total Rounds 2
- Last Round Grant — $14.86M
- First Round $14.86M
(Sep 2007)
- Investors Count 1
All 2 funding rounds of Regeneron Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in Regeneron Pharmaceuticals
Regeneron Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Regeneron Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Regeneron Pharmaceuticals
960 people are tracked at Regeneron Pharmaceuticals (453 in leadership, 3 in board & advisors, 504 in team); the tracked headcount is 15,110.
| Name | Role | Group |
|---|---|---|
Leonard Schleifer | Co-Founder & CEO | Leadership |
Nanita Cranford | Vice President, Global Regulatory Operations | Leadership |
Kris Sprague | Global Head, Program And Project Planning | Leadership |
Danielle Clemente | Director HR Business Partner | Leadership |
Leslie Cascone Rohrbacker | Executive Director Human Resources | Leadership |
Barbara Forster | Senior Director, Global Benefits | Leadership |
Jeanne O'Connell | Director QC Technical Resources | Leadership |
George D. Yancopoulos | President & Chief Scientific Officer | Leadership |
Leonard S. Schleifer | Founder, President & CEO | Leadership |
Priscila Gonçalves | Senior Medical Director | Leadership |
Janie Parrino | Global Program Head, Immunology, Inflammation, And Infectious Diseases | Leadership |
Nicole Dossin | Senior Director, Development Program Management (ces And Precision Medicine) | Leadership |
Paulina Olivo Weber | Director, Development Operations And Portfolio Management | Leadership |
Dana Pipkin | National Account Director | Leadership |
Gina Thomas | Vice President Talent Acquisition | Leadership |
Humberto Lara-Guerra | Senior Medical Director Clinical Sciences | Leadership |
Yvette Payne | Director Hematology Field Medical Team | Leadership |
Srinivasan Sadanandhamurthy | Senior Director, Data Engineering | Leadership |
Frank Loganzo | Director, Solution Partner, Research & Preclinical Development IT | Leadership |
Colleen Scott | Director, Talent Management | Leadership |
940 more people are available in the full profile.
Complete people profiles for Regeneron Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol REGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Apr 1991
- Listed onNASDAQ: REGN
- Listed entityRegeneron Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS75886F1075
- Share price$753.12 (-1.27% on the day) · 2026-10-13
- Market capitalisation$77.54B
- Price to earnings18.6
- EPS (diluted, trailing year)$40.46
- Dividend yield0.49%
- Volume (last session)629,557
Financials of Regeneron Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $14.34B | $4.50B | $4.25B |
| 2024 | $14.20B | $4.41B | $4.66B |
| 2023 | $13.12B | $3.95B | $4.77B |
| 2022 | $12.17B | $4.34B | $5.73B |
| 2021 | $16.07B | $8.08B | $9.23B |
Detailed financial statements for Regeneron Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Regeneron Pharmaceuticals
Regeneron Pharmaceuticals has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Checkmate Pharmaceuticals, Decibel Therapeutics and LIBTAYO.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Drug delivery platforms and therapeutics for ophthalmology are developed. | oxular.com | Oxford, United Kingdom | 2014 | Jan 2025 | •••• | |
Medicines are developed to protect, repair, and restore hearing capacity. | decibeltx.com | Cambridge, United States | 2015 | Aug 2023 | •••• | |
Cancer treatment medicine is featured on the official website. | libtayo.com | Tarrytown, United States | 2012 | Jun 2022 | •••• | |
Oligonucleotides for cancer immunotherapy are developed via innate immune activation. | checkmatepharma.com | Cambridge, United States | 2015 | Apr 2022 | •••• |
Complete acquisition details for Regeneron Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Regeneron Pharmaceuticals
8 dated milestones of Regeneron Pharmaceuticals across 37 years, from founding to its latest funding, stage changes and deals.
- Founded Regeneron Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $14.9M.
- Funding Latest funding round, Grant, of $14.9M.
- Acquisition Acquires Checkmate Pharmaceuticals.
- Acquisition Acquires LIBTAYO.
- Acquisition Acquires Decibel Therapeutics.
- Acquisition Acquires Oxular.
Competitors of Regeneron Pharmaceuticals
Regeneron Pharmaceuticals has 9 listed competitors in our database, 7 of them funded. They include Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| alxoncology.com | 2015 | Burlingame, United States | $123.02M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| ventyxbio.com | 2018 | Encinitas, United States | $165.3M | 79 | Therapeutics for autoimmune diseases are developed by the company. |
Detailed competitors of Regeneron Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Regeneron Pharmaceuticals
The website of Regeneron Pharmaceuticals (regeneron.com) receives about 324.3K visits a month and ranks #154,450 among all websites worldwide, #9,932 in Biology.
- Monthly visits324.3K
▲ 21.4% vs previous month
- Unique visitors117.5K
per month
- Global rank#154,450
among all websites
- Category rank#9,932
Science and Education · Biology
- Bounce rate45%
- Pages per visit3.2
- Average visit2 min 19 sec
- DevicesDesktop 51% · Mobile 49%
Websites whose visitors overlap most with Regeneron Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biorxiv.org | 100% | 3M | #19,954 | View details | |
| biospace.com | 96% | 720.1K | #88,394 | View details | |
| chemocentryx.com | 96% | – | – | View details | |
| cell.com | 93% | 5M | #14,619 | View details | |
| frontiersin.org | 92% | 11.4M | #6,155 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Regeneron Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Regeneron Pharmaceuticals (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Regeneron Pharmaceuticals
Complete news archive for Regeneron Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Regeneron Pharmaceuticals
Regeneron Pharmaceuticals was founded in 1988 and raised its 1st funding round 19 years after it was founded.
Regeneron Pharmaceuticals is headquartered in Tarrytown, United States. It is registered at Tarrytown, New York, United States.
Leonard Schleifer is the current CEO of Regeneron Pharmaceuticals. They have also founded this company.
Regeneron Pharmaceuticals has 15,110 employees.
Annual revenue of Regeneron Pharmaceuticals is $14.34B as on Dec 31, 2025.
Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, United States. Antibodies are developed by the company for applications in oncology, ophthalmology, and immunology. Key products include ARCALYST for inflammation, EYLEA for eye conditions, and PRALUENT as a PCSK9 inhibitor. Phase 3 and 2 pipelines address rheumatoid arthritis, asthma, atopic dermatitis, and other disorders. Annual revenues reached 12.17 billion in 2022, with net profit at 4.33 billion.
Yes, Regeneron Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol REGN.
Regeneron Pharmaceuticals has made 4 acquisitions, including Checkmate Pharmaceuticals, Decibel Therapeutics, and LIBTAYO.
Regeneron Pharmaceuticals has 1 investor. Key investors include HHS.
The website of Regeneron Pharmaceuticals receives about 324 thousand visits a month and ranks #154,450 among all websites worldwide.